Breccia Massimo, Gentilini Fabiana, Cannella Laura, Latagliata Roberto, Carmosino Ida, Frustaci Annamaria, Alimena Giuliana
Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.
Leuk Res. 2008 Jul;32(7):1022-5. doi: 10.1016/j.leukres.2007.10.016. Epub 2007 Dec 3.
Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases. Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect. We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma.
